Our overall hypothesis is that there are identifiable genetic predispositions to the development of pancreatic cancer. Our overall translational goals are to develop a scientific evidence base to inform genetic counseling and risk assessment of familial pancreatic cancer patients, to identify genetic alterations that are specifically targetable therapeutically, and to identify those high risk relatives who would benefit most from future chemoprevention trials and efforts to screen for early, and therefore potentially curable, pancreatic neoplasia. The goals of this project are to characterize further the phenotype of familial pancreatic cancer, to identify pancreatic cancer susceptibility genes, and to use these discoveries to improve clinical risk assessment for patients and their families. To achieve these goals we will utilize the unique resource of the National Familial Pancreas Tumor Registry, with over 3,900 pancreatic cancer families to conduct detailed analysis of the pathology of both familial and sporadic pancreatic cancer as well as penetrance analysis for established pancreatic cancer genes and environmental risk factors that allow for gene by environment interaction. In addition, candidate genes identified through our ongoing whole genome and exome sequencing individuals from over 100 familial pancreatic cancer families will be evaluated to identify additional pancreatic cancer susceptibility genes. We anticipate that our project will not only identify new pancreatic cancer genes but also quantify the risk of pancreatic cancer associated with these genes translating these findings into the clinical setting.
The goal of this project identify new familial pancreatic cancer genes, quantify the risk of pancreatic cancer associated with these new genes along with established genetic and non-genetic risk factors, and to use these findings to improve risk modeling for pancreatic cancer.
|Llosa, Nicolas J; Cruise, Michael; Tam, Ada et al. (2015) The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5:43-51|
|Eshleman, James R; Norris, Alexis L; Sadakari, Yoshihiko et al. (2015) KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound. Clin Gastroenterol Hepatol 13:963-9.e4|
|Zhen, David B; Rabe, Kari G; Gallinger, Steven et al. (2015) BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med 17:569-77|
|Patel, Kalpesh; Iacobuzio-Donahue, Christine A; Gormley, Paul E et al. (2015) Are we systematically under-dosing patients with fluorouracil? J Clin Oncol 33:e36-7|
|De Remigis, Alessandra; de Gruijl, Tanja D; Uram, Jennifer N et al. (2015) Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. Int J Cancer 136:127-37|
|Sutcliffe, Catherine G; Schultz, Kathleen; Brannock, Julitta M et al. (2015) Do people know whether they are overweight? Concordance of self-reported, interviewer-observed, and measured body size. Cancer Causes Control 26:91-8|
|Black, Chelsea M; Armstrong, Todd D; Jaffee, Elizabeth M (2014) Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice. Cancer Immunol Res 2:307-19|
|Kojima, Masatsugu; Murata, Satoshi; Mekata, Eiji et al. (2014) Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine. J Immunother 37:147-54|
|Wu, Xinyan; Renuse, Santosh; Sahasrabuddhe, Nandini A et al. (2014) Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nat Commun 5:4961|
|Amato, Eliana; Molin, Marco Dal; Mafficini, Andrea et al. (2014) Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 233:217-27|
Showing the most recent 10 out of 633 publications